Live Oak Health Sciences Fund (LOGSX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Live Oak Health Sciences Fund (LOGSX) with AI Score 47/100 (Weak). Live Oak Health Sciences Fund (LOGSX) is a mutual fund focused on investing in companies within the healthcare, medicine, and life sciences sectors. The fund primarily invests in U. S. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 16, 2026Live Oak Health Sciences Fund (LOGSX) Financial Services Profile
Live Oak Health Sciences Fund (LOGSX) is a financial services firm specializing in the asset management of healthcare and life science companies. The fund invests primarily in U.S. common stocks, with a smaller allocation to equity REITs, foreign companies, and American Depositary Receipts, offering investors exposure to the health sciences sector.
Investment Thesis
Live Oak Health Sciences Fund presents an investment opportunity within the specialized healthcare and life sciences sectors. The fund's focus on companies involved in research, development, production, and distribution within these fields positions it to benefit from the ongoing growth and innovation in the healthcare industry. With at least 80% of its net assets invested in equity securities of health science companies, LOGSX offers targeted exposure to this sector. The fund's flexibility to invest in equity REITs, foreign companies, and ADRs provides diversification and the potential to capture opportunities beyond the U.S. market. However, the fund's concentration in the healthcare sector also exposes it to sector-specific risks, such as regulatory changes and patent expirations. The fund's beta of 0.64 suggests lower volatility compared to the overall market. As of 2026-03-16, the fund offers no dividend yield.
Based on FMP financials and quantitative analysis
Key Highlights
- The fund invests at least 80% of its net assets in equity securities of health science companies, providing focused exposure to the healthcare sector.
- LOGSX has a beta of 0.64, indicating lower volatility compared to the broader market.
- The fund invests primarily in common stocks of U.S. companies, offering stability and familiarity to investors.
- The fund may invest in equity REITs, common stocks of foreign companies, and American Depositary Receipts (ADRs) to diversify its portfolio.
- As of 2026-03-16, the fund does not offer a dividend yield.
Competitors & Peers
Strengths
- Focused investment strategy in the healthcare sector.
- Potential for high growth due to innovation in healthcare.
- Diversification within the healthcare industry.
- Flexibility to invest in REITs, foreign companies, and ADRs.
Weaknesses
- Concentration risk due to focus on a single sector.
- Sensitivity to regulatory changes and patent expirations in healthcare.
- Dependence on the performance of the healthcare industry.
- Small market capitalization of the fund.
Catalysts
- Ongoing: Continued innovation and technological advancements in the healthcare sector.
- Ongoing: Increasing healthcare spending due to an aging population and rising prevalence of chronic diseases.
- Ongoing: Expansion of healthcare services in emerging markets.
- Upcoming: Potential regulatory approvals for new drugs and medical devices.
Risks
- Potential: Regulatory changes and government policies impacting the healthcare industry.
- Potential: Patent expirations and generic competition affecting pharmaceutical companies.
- Potential: Economic downturn leading to reduced healthcare spending.
- Ongoing: Market volatility and fluctuations in stock prices.
- Ongoing: Concentration risk due to focus on a single sector.
Growth Opportunities
- Increased Healthcare Spending: The global healthcare expenditure is projected to continue its upward trajectory, driven by factors such as an aging population, rising prevalence of chronic diseases, and advancements in medical technology. This trend presents a significant growth opportunity for LOGSX, as increased healthcare spending translates into higher revenues and profits for companies within the fund's portfolio. The global healthcare market is expected to reach trillions of dollars in the coming years, providing a vast landscape for investment and growth. This ongoing trend will likely continue beyond 2026.
- Technological Advancements in Healthcare: The healthcare industry is undergoing a rapid transformation driven by technological advancements such as artificial intelligence, telemedicine, and personalized medicine. These innovations are creating new opportunities for companies involved in the development and implementation of these technologies. LOGSX can capitalize on this trend by investing in companies that are at the forefront of healthcare innovation, driving growth and enhancing patient outcomes. The market for healthcare technology is expected to grow substantially in the next decade, offering significant potential for returns.
- Aging Population: The global population is aging, with a growing proportion of individuals aged 65 and older. This demographic shift is driving increased demand for healthcare services, pharmaceuticals, and medical devices. LOGSX is well-positioned to benefit from this trend by investing in companies that cater to the needs of the aging population. The market for geriatric care and related products and services is expected to expand significantly in the coming years, providing a long-term growth opportunity for the fund.
- Expansion into Emerging Markets: Emerging markets are experiencing rapid economic growth and increasing access to healthcare services. This presents a significant opportunity for LOGSX to expand its investment universe and tap into the growth potential of healthcare companies in these regions. By investing in companies that are expanding their operations in emerging markets, the fund can diversify its portfolio and enhance its returns. The growth of healthcare markets in Asia, Latin America, and Africa is expected to outpace developed markets in the coming years.
- Increasing Demand for Personalized Medicine: Personalized medicine, which tailors medical treatment to individual patient characteristics, is gaining traction in the healthcare industry. This approach requires advanced diagnostics, targeted therapies, and sophisticated data analytics. LOGSX can capitalize on this trend by investing in companies that are developing and commercializing personalized medicine solutions. The market for personalized medicine is expected to grow rapidly as healthcare providers increasingly adopt this approach to improve patient outcomes and reduce healthcare costs. This trend is expected to continue beyond 2026.
Opportunities
- Expansion into emerging markets with growing healthcare needs.
- Increased investment in personalized medicine and healthcare technology.
- Growing demand for healthcare services due to an aging population.
- Potential for acquisitions or partnerships to expand the fund's reach.
Threats
- Increased competition from other healthcare-focused funds.
- Economic downturn affecting healthcare spending.
- Unexpected adverse events impacting healthcare companies.
- Changes in government regulations affecting the healthcare industry.
Competitive Advantages
- Specialized Focus: LOGSX's focus on the healthcare and life sciences sectors provides a degree of specialization and expertise.
- Established Investment Process: The fund's established investment process and experienced management team contribute to its competitive advantage.
- Diversification within Healthcare: The fund's ability to invest across different segments of the healthcare industry provides diversification and reduces risk.
About LOGSX
Live Oak Health Sciences Fund (LOGSX) is a mutual fund dedicated to investing in the dynamic and growing healthcare, medicine, and life sciences sectors. The fund's primary investment strategy involves allocating capital to common stocks of companies actively engaged in the research, development, production, or distribution of related products and services. LOGSX aims to provide investors with a focused approach to participate in the potential growth and innovation within the health sciences industry. The fund typically invests at least 80% of its net assets in equity securities of health science companies, ensuring a significant concentration in this sector. While the fund primarily focuses on U.S. companies, it maintains the flexibility to invest, to a lesser extent, in equity REITs, common stocks of foreign companies, and American Depositary Receipts (ADRs) that align with its investment criteria. This diversification allows the fund to capture opportunities beyond the U.S. market and enhance its overall portfolio performance. LOGSX offers investors a vehicle to access a specialized segment of the market, leveraging the expertise of its management team in identifying promising companies within the health sciences landscape. The fund's investment approach is designed to capitalize on the long-term growth potential of the healthcare industry, driven by factors such as an aging population, technological advancements, and increasing demand for healthcare services.
What They Do
- Invests primarily in common stocks of companies engaged in health care, medicine, or the life sciences.
- Allocates at least 80% of net assets to equity securities of health science companies.
- Focuses primarily on common stocks of U.S. companies.
- May invest in equity REITs, common stocks of foreign companies, and American Depositary Receipts (ADRs).
- Aims to provide investors with exposure to the growth potential of the health sciences sector.
Business Model
- Generates revenue through management fees charged as a percentage of assets under management (AUM).
- Aims to increase AUM by attracting new investors and retaining existing ones through strong performance.
- Invests in companies within the healthcare, medicine, and life sciences sectors to generate capital appreciation.
Industry Context
The asset management industry is characterized by intense competition and evolving market dynamics. Funds like LOGSX, which specialize in specific sectors such as healthcare, aim to differentiate themselves by offering targeted exposure to high-growth areas. The healthcare sector is driven by factors such as an aging population, technological advancements, and increasing healthcare spending. The competitive landscape includes both specialized healthcare funds and broader market funds that may have some allocation to healthcare stocks. Funds must navigate regulatory changes, market volatility, and the need to deliver consistent returns to attract and retain investors.
Key Customers
- Individual investors seeking exposure to the healthcare sector.
- Institutional investors looking for specialized investment strategies.
- Retirement savers seeking long-term growth in the healthcare industry.
Financials
Chart & Info
Live Oak Health Sciences Fund (LOGSX) stock price: Price data unavailable
Latest News
No recent news available for LOGSX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LOGSX.
Price Targets
Wall Street price target analysis for LOGSX.
MoonshotScore
What does this score mean?
The MoonshotScore rates LOGSX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Live Oak Health Sciences Fund Stock: Key Questions Answered
What does Live Oak Health Sciences Fund do?
Live Oak Health Sciences Fund (LOGSX) is a mutual fund that specializes in investing in companies within the healthcare, medicine, and life sciences sectors. The fund's primary objective is to provide investors with exposure to the growth potential of these industries by investing at least 80% of its net assets in equity securities of health science companies. LOGSX focuses primarily on U.S. common stocks but may also invest in equity REITs, foreign companies, and American Depositary Receipts (ADRs). The fund aims to capitalize on the long-term trends driving the healthcare sector, such as an aging population and technological advancements.
What are the main risks for LOGSX?
The main risks for Live Oak Health Sciences Fund (LOGSX) stem from its concentration in the healthcare sector. Regulatory changes, such as drug pricing policies or healthcare reforms, can significantly impact the profitability of companies within the fund's portfolio. Patent expirations and generic competition can also erode the revenues of pharmaceutical companies. Additionally, economic downturns may lead to reduced healthcare spending, affecting the demand for healthcare services and products. Market volatility and fluctuations in stock prices pose further risks to the fund's performance. Investors should be aware of these sector-specific and market-related risks when considering an investment in LOGSX.
How does Live Oak Health Sciences Fund make money in financial services?
Live Oak Health Sciences Fund generates revenue primarily through management fees charged as a percentage of its assets under management (AUM). These fees are designed to cover the costs associated with managing the fund, including research, portfolio management, and administrative expenses. The fund's profitability is directly tied to its ability to attract and retain investors, as a larger AUM base translates into higher management fee revenue. Additionally, the fund may generate revenue through securities lending activities, where it lends out a portion of its portfolio to other financial institutions for a fee. The success of LOGSX's business model depends on its ability to deliver competitive returns and maintain a strong reputation within the asset management industry.
What are the key factors to evaluate for LOGSX?
Live Oak Health Sciences Fund (LOGSX) currently holds an AI score of 47/100, indicating low score. Key strength: Focused investment strategy in the healthcare sector.. Primary risk to monitor: Potential: Regulatory changes and government policies impacting the healthcare industry.. This is not financial advice.
How frequently does LOGSX data refresh on this page?
LOGSX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LOGSX's recent stock price performance?
Recent price movement in Live Oak Health Sciences Fund (LOGSX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focused investment strategy in the healthcare sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LOGSX overvalued or undervalued right now?
Determining whether Live Oak Health Sciences Fund (LOGSX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LOGSX?
Before investing in Live Oak Health Sciences Fund (LOGSX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- Investment decisions should be made based on individual circumstances and consultation with a financial advisor.